Liver X receptors (LXRs) are nuclear receptors previously identified to be important in lipid metabolism. Recent reports suggest that LXR agonists also exhibit anti-inflammatory properties in mouse models of atherosclerosis and contact dermatitis. In the present study, we investigated the effects of LXR agonists on mouse microglia and astrocytes. When chronically activated, these resident-CNS glia have been implicated in the pathology of neuroinflammatory disorders including multiple sclerosis (MS). Our studies demonstrated for the first time that LXR agonists inhibited the production of nitric oxide, the pro-inflammatory cytokines IL-1β and IL-6 and the chemokine MCP-1 from LPSstimulated microglia and astrocytes. Furthermore, LXR agonists inhibited LPS-induction of nuclear factor-kappa B (NF-κB) DNA-binding activity. These agonists also blocked LPS-induction of IκB-α protein degradation in microglia, suggesting a mechanism by which these agonists modulate NF-κB DNA-binding activity. These studies suggest that LXR agonists suppress the production of pro-inflammatory molecules by CNS glia, at least in part, by modulating NF-κB-signaling pathways. Retinoid X receptors (RXRs) physically interact with LXR receptors, and the resulting obligate heterodimer regulates the expression of LXR-responsive genes. Interestingly, a combination of LXR and RXR agonists additively suppressed the production of NO by microglia and astrocytes. Collectively, these studies suggest that LXR agonists may be effective in the treatment of neuroinflammatory diseases including MS.
Introduction
Multiple sclerosis (MS) affects approximately 400,000 people in the United States (Anderson et al., 1992) . This disorder commonly strikes young adults and can profoundly affect quality of life (McFarlin and McFarland, 1982a,b) . Multiple factors have been proposed to contribute to the development of MS, including viral infections, environmental factors and genetic background (Gilden, 2005; Marrie, 2004) . MS is thought to be an autoimmune disease characterized by immune mediated myelin destruction and axonal transection. Currently available treatments for MS are modestly efficacious, and there is no cure (Cohen et al., 1999; Wekerle, 2002) . Therefore, a great need exists for developing novel MS therapies.
Liver X receptors (LXRs) are nuclear receptors involved in the regulation of lipid metabolism (Cao et al., 2004; Edwards et al., 2002) . Two LXR receptor subtypes exist; LXR-α, which is expressed on cells including macrophages and hepatocytes, and LXR-β, which is ubiquitously expressed (Janowski et al., 1999) . Recent studies indicate that LXR agonists also modulate inflammatory responses. For example, LXR agonists suppressed inflammation in mouse models of atherosclerosis and contact dermatitis (Fowler et al., 2003; Joseph et al., 2003) . This suggests that LXR agonists may be effective in the treatment of neuroinflammatory disorders including MS.
Microglia are immune cells that reside in the CNS. They are antigen presenting cells and upon activation are capable of phagocytosis and the production of various pro-inflammatory molecules such as nitric oxide (NO) and
